Source: Annual Congress 2001 - New treatments for asthma and COPD: PDE4 inhibitors and anti-IGE
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Ouagued, C. Martin-Chouly, C. Leportier, C. Belleguic, P. Delaval, V. Lagente, C. Danzin, C. Bertrand, M. P. Pruniaux (Fresnes, Rennes, France). The novel phosphodiesterase 4 inhibitor CI-1044 inhibits in vitro LPS-induced TNFα production in whole blood of COPD patients. Eur Respir J 2001; 16: Suppl. 31, 333

Member's Comments

No comment yet.

Related content which might interest you: The selective phosphodiesterase 4 inhibitor, cilomilast, inhibits interleukin-8-induced pulmonary neutrophil accumulation in the rabbit Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001 The phosphodiesterase 4 inhibitor SB 207499 selectively inhibits neutrophil functions Source: Eur Respir J 2001; 18: Suppl. 33, 34s Year: 2001 Dose-dependent inhibitory effect of Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, on allergen-induced early and late asthmatic reaction Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002 Roflumilast potently inhibits CXCL1 mediated neutrophil migration in COPD patients Source: Annual Congress 2011 - COPD: clinical studies and animal cell models Year: 2011 In vitro and in vivo anti-inflammatory activity of the novel PDE4 inhibitor roflumilast Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001 Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019 Inhibition by roflumilast vs cilomilast of pulmonary leukocyte accumulation and TNFα release in a rat model of LPS-induced pulmonary neutrophilia Source: Eur Respir J 2003; 22: Suppl. 45, 107s Year: 2003 Suppressive effect of novel phosphodiesterase4 (PDE4) inhibitor ONO-6126 on TNF-α release was increased after repeated oral administration in healthy Japanese subjects Source: Annual Congress 2003 - Novel drugs under development for the treatment of respiratory diseases Year: 2003 N-Acetylcysteine inhibits eotaxin and MCP-1 release in human airway smooth muscle cells in vitro through the inhibition of ROS production, resulting in a decrease of p38 MAP kinase activation Source: Eur Respir J 2002; 20: Suppl. 38, 170s Year: 2002 Cilomilast, a second generation phosphodiestease 4 inhibitor, in combination with PGE2 attenuates fMLP, IL-8 and cigarette smoke-induced effects on the mechanical and functional properties of neutrophils Source: Eur Respir J 2001; 18: Suppl. 33, 161s Year: 2001 Effects of a selective phosphodiesterase IV and V inhibitor in a murine model of chronic asthma Source: Eur Respir J 2004; 24: Suppl. 48, 128s Year: 2004 Effects of pendrin inhibitor (PDI_C01) in vitro, and in vivo models of lipopolysaccharide-induced airway inflammation. Source: International Congress 2019 – Biomarkers, laboratory findings and pre-clinical data in acute respiratory failure Year: 2019 In vitro pharmacological characterization of the potent, lung selective pan-JAK inhibitor TD-8236 Source: International Congress 2019 – Advances in asthma pharmacology Year: 2019 Effect of a pan-JAK inhibitor pyridone 6 on airway responses in murine asthma model Source: Annual Congress 2010 - Asthma: basic science and clinical studies Year: 2010 Effect of PDE4 inhibitors on MAPK activation and IL-8 production on A549 cells following the induction of oxidative stress Source: Eur Respir J 2005; 26: Suppl. 49, 99s Year: 2005 Inhibition of LPS-induced cytokine/chemokine production from human lung macrophages by roflumilast is enabled by autocrine PGE2 Source: Annual Congress 2010 - Macrophages: cell biology and disease-specific characteristics Year: 2010 In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 Effects of CHF6297, a potent and selective p38a MAPK inhibitor, in murine models of steroid resistant lung inflammation Source: International Congress 2017 – Towards new anti-inflammatory and anti-fibrotic agents Year: 2017 Peroxiredoxin 6 attenuates lipopolysaccharide-induced plasminogen activatro inhibitor 1 expression by regulating autophagy Source: Annual Congress 2012 - Lung injury and repair: reactive oxygen species and beyond Year: 2012 Efficacy of the selective phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004, in a rat model of neutrophilic lung inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001